The week in pharma: action, reaction and insight – week to November 18, 2022

By Barbara Obstoj-Cardwell. Editor

Among regulatory developments last week, the UK’s AstraZeneca received approval from the US food and Drug Administration (FDA) for its checkpoint inhibitor Imfinzi plus Imjudo for the treatment of lung cancer. Adding to the litany of failures in the search for an effective Alzheimer’s treatment, Swiss giant Roche last Monday released new clinical trial data on its candidate gantenerumab which did not meet the primary endpoint of the study. On the deal-making front, US companies POINT Biopharma and Lantheus Holdings entered into a licensing agreement for PNT2002 and PNT2003, two novel radiopharmaceuticals for cancer. US biotech Arcutis Biotherapies last Wednesday released positive Phase III results for its investigational atopic dermatitis drug roflumilast.

Incorporating Imjudo into AstraZeneca valuation following approvals